New hepatitis B treatment as NZ fights resistance
23 July 2009
Becky Debens
Hepatitis B patients in New Zealand will gain access to a new drug from next month in a bid to prevent the emergence of resistance against other available treatments.
Bristol-Myers Squibb's Baraclude (entecavir) will be funded under a Special Authority, as a first-line treatment for hepatitis...
Please Login to read the full article.
23 July 2009
Becky Debens
Bristol-Myers Squibb's Baraclude (entecavir) will be funded under a Special Authority, as a first-line treatment for hepatitis...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: With wish granted, Collins forges ahead with new translational science centre
- Bristol-Myers scoops Inhibitex for $2.5bn
- Positive Phase III results confirm Q2 2012 filing for Gilead's HIV drug booster, cobicistat
- Transgene puts its best foot forward at first R&D day
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
